Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Macitentan Pediatric Formulations in Healthy Adults
NCT04963439Phase 1Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jul 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of macitentan in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Maximum Observed Plasma Analyte Concentration at Day 10, Area Under the Plasma Analyte Concentration-time Curve from Time Zero to Time of the Last Quantifiable Concentration at Day 10 and 1 more. Started Jul 2021; status: completed.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04963439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04963439.